Genentech Girds For Competition From Generics And Big Pharma
Genentech will develop a defensive plan for each of its products in preparation for the potential introduction of follow-on biologics, Exec VP-Commercial Operations Ian Clark said during an investor update meeting March 17
You may also be interested in...
Genentech/Biogen Idec are pricing Rituxan (rituximab) for rheumatoid arthritis at a lower cost for most patients than the closest comparable biologic, Bristol-Myers Squibb's Orencia (abatacept)
Genentech and marketing partner OSI are highlighting the overall survival benefit of combination use with Tarceva over gemcitabine (Lilly's Gemzar) plus placebo for treatment of advanced pancreatic cancer
As Genentech enters the final quarter of its multi-year growth plan, the firm is on track to meet or exceed the development and product approval goals set out in its "5x5" plan for the period from 1999 to 2005